| 前收盘价格 | 29.70 |
| 收盘价格 | 29.60 |
| 成交量 | 1,909,000 |
| 平均成交量 (3个月) | 1,526,167 |
| 市值 | 8,404,794,880 |
| 价格/销量 (P/S) | 88.78 |
| 股市价格/股市净资产 (P/B) | 2.92 |
| 52周波幅 | |
| 利润日期 | 27 Aug 2024 |
| 营业利益率 (TTM) | -719.51% |
| 稀释每股收益 (EPS TTM) | -3.05 |
| 季度收入增长率 (YOY) | -83.30% |
| 总债务/股东权益 (D/E MRQ) | 28.49% |
| 流动比率 (MRQ) | 4.98 |
| 营业现金流 (OCF TTM) | -709.18 M |
| 杠杆自由现金流 (LFCF TTM) | -658.76 M |
| 资产报酬率 (ROA TTM) | -13.19% |
| 股东权益报酬率 (ROE TTM) | -24.70% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (HK) | 混合的 | 混合的 |
| Biotechnology (全球的) | 混合的 | 混合的 | |
| 股票 | KEYMED BIO-B | - | - |
AIStockmoo 评分
0.0
| 分析师共识 | 0.0 |
| 内部交易活动 | NA |
| 价格波动 | 0.5 |
| 技术平均移动指标 | 1.5 |
| 技术振荡指标 | -2.0 |
| 平均 | 0.00 |
相关股票
| 股票 | 市值 | DY | P/E（TTM） | P/B |
|---|---|---|---|---|
| KEYMED BIO-B | 8 B | - | - | 2.92 |
| 3SBIO | 15 B | 3.86% | 8.67 | 0.910 |
| HAOHAI BIOTEC | 15 B | 4.37% | 14.16 | 0.960 |
| AKESO | 55 B | - | - | 9.50 |
| INNOVENT BIO | 53 B | - | - | 4.54 |
| BEIGENE | 195 B | - | - | 6.93 |
|
Keymed Biosciences Inc is a biotechnology company with multiple clinical-stage assets. The company is focused on the in-house discovery and development of biological therapies that address large underserved medical needs in the autoimmune and oncology therapeutic areas. Its clinical-stage drug candidates include CM310, CM326, CM313, and CM336 among others. The company is engaged in biopharmaceutical research and development, which is regarded as a single reportable segment. Geographically, it generates a majority of its revenue from overseas markets and the rest from Mainland China. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Mid Value |
| 内部持股比例 | 32.62% |
| 机构持股比例 | 29.45% |
该时间范围内无数据。
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合